BMW's Grand-Tourer Exit and the i3 Gamble: A Pivot Priced for Peril

BMW ends 8 Series production, pivots to Alpina for luxury halo, as China sales drop 20% and EBIT margin halves to 2.3%.

The decision to kill the 8 Series without a direct successor is more than a product-line trim — it is a strategic confession. When production of the coupé, cabriolet, and Gran Coupé wound down at the Dingolfing plant in April 2026, BMW effectively admitted that pouring Neue Klasse development money into a low-volume halo model made no financial sense. A senior manager told Automotive News and BMWBLOG that transferring the 8er's technology into the new electric architecture simply wasn't feasible.

That retreat from the niche segment leaves a conspicuous gap at the top of the range, but the company has a plan: Alpina. Fully absorbed as a standalone brand since the start of 2026, the performance marque is being repositioned to carry the exclusive grand-tourer mantle. At the Monterey Car Week in mid-August, BMW unveiled the "Vision BMW Alpina" — a 5.2-meter V8 concept that could slot neatly into the role the 8er once occupied. The move lets the group keep a foothold in the margin-rich luxury tier while the core brand concentrates its engineering firepower on electric scale.

For shareholders, the calculus is blunt. A prestige model disappears, but development costs disappear with it — a trade-off that matters at a moment when China's demand slump is squeezing the automotive margin. The half-year report, published on July 30, laid the damage bare: the automotive EBIT margin collapsed from 5.4 percent to 2.3 percent, and group net profit tumbled 35.1 percent. China, the historical profit engine, saw first-half sales drop 20.4 percent, with the second quarter alone down a brutal 30.2 percent.

The stock, meanwhile, is hugging the floor. Shares closed Thursday at EUR 57.86, just 2.6 percent above the 52-week low of EUR 56.40 and roughly 41 percent below the early-December peak. The year-to-date decline stands at 38 percent. RBC trimmed its price target in mid-August from EUR 62 to EUR 60, keeping a "Sector Perform" rating; analyst Tom Narayan pointed to weak China sales and intensifying competition. Bernstein Research had already cut its target on July 31 from EUR 85 to EUR 82, though it retained an "Outperform" — a sign that even the bulls are recalibrating.

Management is fighting back on multiple fronts. A voluntary severance program covering around 8,000 positions, concentrated in Germany and provisioned at roughly EUR 1 billion, is slated to begin in October. The company has also been buying back stock — between July and August, it repurchased about 1.76 million shares at prices ranging from EUR 56.76 to EUR 61. And a long-running dispute with AUMOVIO has been settled, with BMW awarding contracts worth over EUR 1 billion.

The real test, though, is whether the Neue Klasse can offset the China bleed. The i3's series production started at the Munich plant in early August, following last year's iX3 launch, and first European deliveries are due this autumn. BMW says it already holds roughly 100,000 pre-orders for the iX3 worldwide. The technology is compelling on paper: 800-volt charging and up to 912 kilometers of WLTP range for the i3. European BEV deliveries rose 5.2 percent in the second quarter, with the iX3 ramp-up driving a 38 percent jump in that region — and the European market as a whole grew 5.4 percent in the first half.

The bull case rests on that momentum translating into sustained delivery numbers, which would give BMW its first genuine product-driven narrative in years, reinforced by cost cuts and capital returns. The bear case is equally stark: a 30 percent quarterly collapse in China may be structural, not cyclical, and no European EV success can quickly fill that hole. The full-year automotive margin forecast of just 1 to 3 percent underscores how thin the buffer is. Even the planned agency-model overhaul has been pushed back to no earlier than July 2028 — a sign of caution on the distribution front.

The technical picture offers little clarity. The RSI sits at 41.2, firmly in neutral territory, giving traders no decisive signal. With the stock barely above its yearly low, the next catalyst is concrete: third-quarter delivery figures will show whether those 100,000 iX3 pre-orders convert into actual sales, and whether Dorothea von Boxberg, who takes over as personnel chief on September 1, can execute the workforce reduction without friction. Until then, the shares are likely to remain pinned between hope and the floor.